BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 8937853)

  • 1. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
    Kocarek TA; Reddy AB
    Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative regulation by dexamethasone of fluvastatin-inducible CYP2B expression in primary cultures of rat hepatocytes: role of CYP3A.
    Kocarek TA; Reddy AB
    Biochem Pharmacol; 1998 May; 55(9):1435-43. PubMed ID: 10076536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes.
    Kocarek TA; Dahn MS; Cai H; Strom SC; Mercer-Haines NA
    Drug Metab Dispos; 2002 Dec; 30(12):1400-5. PubMed ID: 12433810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
    Transon C; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of phenobarbital-inducible cytochrome P450 2B1/2 mRNA by lovastatin and oxysterols in primary cultures of adult rat hepatocytes.
    Kocarek TA; Schuetz EG; Guzelian PS
    Toxicol Appl Pharmacol; 1993 Jun; 120(2):298-307. PubMed ID: 8511800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the induction of rat hepatic CYP1A, CYP2B, CYP3A and CYP4A subfamily form mRNAs in vivo and in vitro using precision-cut rat liver slices.
    Meredith C; Scott MP; Renwick AB; Price RJ; Lake BG
    Xenobiotica; 2003 May; 33(5):511-27. PubMed ID: 12746107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver.
    Kocarek TA; Kraniak JM; Reddy AB
    Mol Pharmacol; 1998 Sep; 54(3):474-84. PubMed ID: 9730906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
    Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
    J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription.
    MascarĂ³ C; Ortiz JA; Ramos MM; Haro D; Hegardt FG
    Arch Biochem Biophys; 2000 Feb; 374(2):286-92. PubMed ID: 10666309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of xenobiotic-inducible cytochrome P450 gene expression by dexamethasone in primary rat hepatocytes.
    Sidhu JS; Omiecinski CJ
    Pharmacogenetics; 1995 Feb; 5(1):24-36. PubMed ID: 7773300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
    Yamamoto A; Hoshi K; Ichihara K
    Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
    Shaw MK; Newton RS; Sliskovic DR; Roth BD; Ferguson E; Krause BR
    Biochem Biophys Res Commun; 1990 Jul; 170(2):726-34. PubMed ID: 2166504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
    Lee CK; Choi JS; Choi DH
    Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
    Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
    Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.